Volume 27, Number 4—April 2021
Dispatch
Genomic Characterizations of Clade III Lineage of Candida auris, California, USA
Table 2
Antifungal susceptibility results for Candida auris isolates, Los Angeles, California, USA, 2019–2020*
| Antifungal | MIC, μg/mL (interpretation)† |
|||||
|---|---|---|---|---|---|---|
| UCLA_A1 | UCLA_A2 | UCLA_C1 | UCLA_D1 | UCLA_E1 | UCLA_F1 | |
| Amphotericin B | 2 (R) | 2 (R) | 2 (R) | 2 (R) | 2 (R) | 2 (R) |
| Fluconazole | >64 (R) | >64 (R) | >64 (R) | >64 (R) | >64 (R) | >64 (R) |
| Voriconazole | 2 | 1 | 1 | 0.5 | 0.5 | 2 |
| Itraconazole | 1 | 1 | 0.5 | 0.25 | 0.25 | 1 |
| Posaconazole | 0.06 | 0.12 | ≤0.03 | ≤0.03 | 0.06 | 0.06 |
| Anidulafungin | 0.5 (S) | 0.12 (S) | 0.25 (S) | 0.12 (S) | 0.06 (S) | 1 (S) |
| Caspofungin | 0.5 (S) | 0.12 (S) | 0.5 (S) | 0.5 (S) | 0.12 (S) | 0.5 (S) |
| Micafungin | 0.25 (S) | 0.25 (S) | 0.25 (S) | 0.12 (S) | 0.25 (S) | 0.25 (S) |
*I, intermediate; R, resistant; S, susceptible. †MIC testing was conducted on panels prepared in-house in accordance with Clinical and Laboratory Standards Institute guidelines (https://standards.globalspec.com/std/10266416/CLSI%20M27). Interpretive breakpoints were defined by the CDC Antifungal Susceptibility Testing and Interpretation guidelines for C. auris (https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html), which were adapted from interpretive criteria for closely related Candida spp. Tentative breakpoints for the following antifungal drugs were: amphotericin B (>2 μg/mL), fluconazole (>32 μg/mL), anidulafungin (>4 μg/mL), caspofungin (>2 μg/mL), and micafungin (>4 μg/mL).